-
Cell: An effective antibody against the new coronavirus has been identified to protect infected hamsters from lung lesions.
Time of Update: 2020-10-05
a new study, researchers from the German Center for Neurodegenerative Diseases and berlin's Schalette School of Medicine identified highly effective antibodies against SARS-CoV-2 and are working on a passive immune strategy.
-
The body's immune system may have another new function to --- depression.
Time of Update: 2020-10-05
25, 2020 /--- In a new study, researchers from yale University School of Medicine and other research institutions compared immune system cells in the spinal fluid of multiple sclerosis (MS) patients and healthy subjects and found that inflammatory autoimmune responses found in healthy people's spinal fluid were similar to autoimmune responses associated with neurodegenerative diseases such as multiple sclerosis.
-
New drug for rheumatoid arthritis (RA)! Gilead's oral JAK1 inhibitor Jyseleca (filgotinib) is approved by the European Union and Japan!
Time of Update: 2020-10-05
-- -- Gilead and partner Galapagos NV recently jointly announced that the European Commission (EC) has approved Jyseleca (filgotinib, 200mg and 100mg tablets), an oral selective JAK1 inhibitor used to treat adult patients with moderate to severe rheumatoid arthritis (RA) who have inadequate or insatiable response to one or more disease-modified anti-rheumatoid drugs (DMARD).
-
Two Science papers have revealed that some cases of severe COVID-19 are linked to genetic mutations or attacks on the body's autoantibodies.
Time of Update: 2020-10-05
," said Jean-Laurent Casanova, a researcher at Rockefeller University in the United States and co-author of the two papers, that the observation of these harmful antibodies in so many patients (101 out of 987 patients) was a "startling discovery." " papers explain for the first time why COVID-19 is so severe in some people, while most others are not infected with the same virus.
-
How can a variety of experimental therapies improve human health?
Time of Update: 2020-10-05
"!-- webeditor:page title" -- In this article, several important research results have been compiled to explain how scientists can use a variety of experimental therapies to improve human health? Shar
-
Recent important research results of intestinal microorganisms are interpreted!
Time of Update: 2020-10-05
In !--," the editor summarizes several important research findings to jointly interpret recent discoveries by scientists in the field of microbiome research! Learn with you! Picture: CC0 Public Domain
-
Multiple articles to interpret the new progress of rheumatoid arthritis research!
Time of Update: 2020-10-05
In !-- paper, we take stock of the research achievements made by scientists in the field of rheumatoid arthritis and share them with you! Picture: Science 1 PLoS Med: Are rheumatoid arthritis two diff
-
FDA grants Avacopan a new drug application to treat ANCA-related vasculitis (NDA)
Time of Update: 2020-10-04
NDA was supported by data from the Global Phase III ADVOCATE trial, which showed that the avacopan group had a statistical advantage in maintaining 52-week mitigation compared to the Pernisson group.
-
Ann Rheum Dis: Risk of venous thrombosis in knee, hip and hand osteoarthritis.
Time of Update: 2020-10-04
Each patient with osteoarthritis with knee joint (n=20,696), hip (n=10,411), or hand (n=6329) matched five patients with non-osteoarthritis based on age, sex, group time and body mass index.
-
NEJM: Belle wood monotherapy active lupus nephritis Phase III clinical success.
Time of Update: 2020-10-04
in this Phase III, multi-country, multi-center, randomized, double-blind, placebo-controlled study, adult patients with active lupus nephritis from 21 countries were involved in mycophenolate or cyclophosphamide-thiopental On the basis of standard treatment, intravenous belimu monoantigen (10 mg per kilogram of body weight) or placebo was randomly administered for 104 weeks, and the main endpoint of the study was improved renal function after treatment (defined as the ratio of urine protein to creatinine.
-
Ann Rheum Dis: Genomic risk score for early-onset idlytogenic arthritis and its subtypes.
Time of Update: 2020-10-04
the results were as follows: in the UK queue alone, the area under the working characteristic curve (AUC) of the GRS subjects was 0.670, while in the US and Australia the AUC was 0.657 and 0.671, respectively.
-
Sanofi/Regenerative Dupixent has been recognized by the FDA as a breakthrough therapy.
Time of Update: 2020-10-04
, Dupixent has conducted 50 clinical trials in more than 10,000 patients for a variety of chronic diseases caused by type 2 inflammation.
-
AbbVie submitted a marketing application to the U.S. and European Drug Administration to use the JAK inhibitor Rinvoq for the treatment of psoriasis arthritis.
Time of Update: 2020-10-03
AbbVie has submitted a marketing application to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its new adaptation of the JAK inhibitor Rinvoq (upadacitinib) for the treatment of adult patients with active psoriasis arthritis.
-
JAK inhibitor Rinvoq treats endexual dermatitis: Phase III clinical efficacy is significant.
Time of Update: 2020-10-03
Photo Source: The results showed a significant increase in skin removal and itching reduction in patients treated with 15 mg/30 mg of Rinvoq at the 16th week compared to placebo, with 60% and 73% of patients reaching EASI 75, respectively, compared to 13% in the placebo group.
-
Gospel for patients with chronic skin and respiratory diseases: FDA approves Dupilumab's 300mg pre-filled pen.
Time of Update: 2020-10-03
Recently, the FDA has approved Dupilumab's 300mg single-dose pre-fill pen for all Dupixent adaptations in patients 12 years of age and older, including epithelial dermatitis, asthma and chronic nasal sinusitis with nasal dipherone (CRSwNP).
Dupixent pre-filled pen will make it easier for patients to inject." .
-
OCC 2020 Hydroxychloroquine's role in immunologic disease-related pulmonary hypertension and its value in neocoopha?
Time of Update: 2020-10-03
On May 29th, at the 14th Oriental Cardiology Conference (OCC2020), Professor Li Mengtao from the Rheumatology Immunology Department of Concord Hospital in Beijing shared with experts the themes "Treatment Options for SLE-PAH Basic Diseases" and "The Role of Hydroxychloroquine in Immune Disease-Related Pulmonary Arterial Hypertension and The Value of Coronary Pneumonia".
-
Novar3 IL-17A monoantigen Cosentyx: Approved by the European Union for first-line treatment of psoriasis children.
Time of Update: 2020-10-03
Novarma's leumelocyte-17A (IL-17A) monoantigen Cosentyx (secukinumab) has been approved by the European Commission for the treatment of children and adolescents aged 6-18 with severe plaque-like psoriasis.
: The approval is based on two Phase 3 studies of children and adolescents aged 6-18 years.
-
Ann Rheum Dis: The safety and efficacy of Bailey wood monotherapy for systemic lupus erythematosus in children.
Time of Update: 2020-10-03
The ongoing Phase 2, Randomized, Placebo-Controlled, Double-Blind Study assessed the efficacy, safety, and pharmacodynamics of intravenous bellewood monotherapy against systemic lupus erythematosus (cSLE) in children.
patients (5-17 years of age) were randomly grouped for intravenous 10mg/kg or placebo treatment every 4 weeks, in addition to standard SLE treatment.
-
J Rheumatol: Hospital burden of coronary disease of granuloma multivascular disease.
Time of Update: 2020-10-02
study analyzed the burden trends of coronary artery disease (CAD) and its two severity manifestations, acute myocardial infarction (AMI) and heart failure (HF), in a sample of GPA hospitalized patients.
analyzed trends in CAD, AMI and HF ratios in all GPA inpatients compared to non-GPA patients.
-
NICE UK has approved for the first time a single anti-Stelara targeting IL-12/IL-23 for the treatment of ulcerative colitis.
Time of Update: 2020-10-02
The National Institute for Health and Clinical Excellence (NICE) has approved Janssen's Stelara (ustekinumab) for the treatment of adult patients with moderate to severe active ulcerative colitis (UC) who are insatiable to conventional therapies or biologics, who do not respond or lose their response after treatment.
